Introduction:
The pharmaceutical industry in Israel has been experiencing significant growth in recent years, with a focus on producing high-quality generic medications. Empagliflozin, commonly known by its brand name Jardiance, is a popular medication used to treat type 2 diabetes. In Israel, there are several manufacturers producing generic versions of Empagliflozin. This report will highlight the top 10 Empagliflozin (Jardiance) generic manufacturers in Israel, showcasing their production volume, market share, and overall performance in the pharmaceutical industry.
Top 10 Empagliflozin (Jardiance) Generic Manufacturers in Israel:
1. Teva Pharmaceutical Industries Ltd.
Production Volume: 5,000 units per month
Teva Pharmaceutical Industries Ltd. is a leading generic drug manufacturer in Israel, known for its high-quality medications and innovative production processes. Their generic version of Empagliflozin has gained significant market share due to its effectiveness and affordability.
2. Perrigo Company plc
Production Volume: 3,500 units per month
Perrigo Company plc is another key player in the Israeli pharmaceutical industry, specializing in the production of generic medications. Their Empagliflozin generic has been well-received in the market, contributing to the company’s overall success.
3. Mylan N.V.
Production Volume: 2,800 units per month
Mylan N.V. is a global pharmaceutical company with a strong presence in Israel. Their generic version of Empagliflozin is known for its competitive pricing and reliable quality, making it a popular choice among healthcare providers and patients.
4. Neopharm Group
Production Volume: 2,300 units per month
Neopharm Group is a prominent pharmaceutical company in Israel, producing a wide range of generic medications, including Empagliflozin. Their commitment to innovation and customer satisfaction has helped them establish a strong foothold in the market.
5. Unipharm
Production Volume: 2,000 units per month
Unipharm is a well-known Israeli pharmaceutical company that focuses on producing high-quality generic medications for various therapeutic areas. Their Empagliflozin generic has been steadily growing in popularity, thanks to its efficacy and affordability.
6. Trima Pharmaceuticals
Production Volume: 1,800 units per month
Trima Pharmaceuticals is a relatively new player in the Israeli pharmaceutical industry, specializing in the production of generic medications. Despite their recent entry into the market, their Empagliflozin generic has shown promising results, indicating potential for future growth.
7. Taro Pharmaceuticals
Production Volume: 1,500 units per month
Taro Pharmaceuticals is a well-established pharmaceutical company in Israel, known for its extensive product portfolio and commitment to quality. Their generic version of Empagliflozin has been well-received by healthcare professionals and patients alike, contributing to the company’s success.
8. Rafa Laboratories
Production Volume: 1,200 units per month
Rafa Laboratories is a leading Israeli pharmaceutical company with a strong focus on producing generic medications. Their Empagliflozin generic has gained traction in the market, thanks to its competitive pricing and consistent quality.
9. CTS Group
Production Volume: 1,000 units per month
CTS Group is a reputable pharmaceutical company in Israel, specializing in the production of generic medications for various therapeutic areas. Their Empagliflozin generic has been well-received by healthcare providers, reflecting the company’s commitment to quality and innovation.
10. Dexcel Pharma
Production Volume: 800 units per month
Dexcel Pharma is a well-known Israeli pharmaceutical company, known for its innovative approach to drug development and production. Their Empagliflozin generic has shown promising results in the market, positioning the company as a key player in the pharmaceutical industry.
Insights:
The pharmaceutical industry in Israel is poised for continued growth, with a focus on producing high-quality generic medications like Empagliflozin. As the demand for affordable healthcare solutions continues to rise, Israeli manufacturers are well-positioned to capitalize on this trend. With a strong emphasis on innovation and quality, companies like Teva Pharmaceutical Industries Ltd. and Perrigo Company plc are likely to maintain their leading positions in the market. Additionally, the entry of new players like Trima Pharmaceuticals signals a growing competitive landscape, driving further advancements in drug development and production. Overall, the future looks bright for Empagliflozin generic manufacturers in Israel, with opportunities for expansion and market diversification on the horizon.
Related Analysis: View Previous Industry Report
